TAVNEOS® (avacopan) No Longer Available for Prescribing in the European Union

CSL has announced that TAVNEOS® (avacopan), a treatment for ANCA-associated vasculitis, will no longer be available for prescribing in the European Union (EU) and European Economic Area (EEA). Physicians are advised to discuss individual treatment plans with patients currently receiving the drug.